A Study Investigating the Safety and Tolerability of Deferiprone in Patients With Friedreich's Ataxia

Model scores of the 29,894 trials active now.

Model score 17% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 15% of the time (95 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2009-07-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: definedleftventricularmutationscore
  Phrases that lowered it: evaluate theto evaluateobjectivethe effecteffect of
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Responsible party: not given (raises risk) · Design
• Phase: 1/2 (raises risk) · Design
• Drug's FAERS reports with a death: 28.6% (raises risk) · Drug's FDA history
• Number of arms: 5 (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 7 (lowers risk) · Who can join
• Drug's FAERS reports marked serious: 100% (raises risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 2 (raises risk) · Sponsor's track record
• Disease area, neurology: Yes (raises risk) · Disease area
• Sponsor's past trials: 1 (lowers risk) · Sponsor's track record
• Drug's FAERS reports before start: 7 (lowers risk) · Drug's FDA history
• Sponsor type: industry (lowers risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study Investigating the Long-term Safety and Efficacy of Deferiprone in Patients With Friedreich's Ataxia NCT00897221 · started 2009 · scored riskier than 90% of active trials completed
• Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration NCT02174848 · started 2014 · scored riskier than 26% of active trials completed
• A Blinded, Placebo-Controlled Study of the Safety and Pharmacokinetics of Single Doses of Intravenous Deferiprone in Healthy Volunteers NCT01989455 · started 2013 · scored riskier than 4% of active trials completed
• Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN) NCT01741532 · started 2012 · scored riskier than 90% of active trials completed
• Study to Assess the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients NCT00697073 · started 2008 · scored riskier than 16% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.